ClinicalTrials.gg
CompletedNCT07653191Updated Jun 17, 2026

Changes in Uterine Artery Resistance Index Following Cervical Conization

An interventional study of Cervical Conization in Cervical Intraepithelial Neoplasia and Uterine Artery Hemodynamics, sponsored by Adana City Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Adana City Training and Research Hospital · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 7 years 11 months after the study started (first participant enrolled Jun 2018, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
Female
01

Study summary

The objective of this prospective study is to evaluate the hemodynamic impact of cervical conization on uterine artery blood flow by focusing on the Resistance Index (RI) as a direct indicator of distal vascular resistance. The central hypothesis is predicated on the physiological principle that the surgical excision and subsequent sealing of terminal cervical branches during conization increases the distal vascular impedance (afterload) encountered by the main uterine artery. Uterine artery Doppler RI measurements are performed preoperatively and at one month postoperatively to assess these alterations.

Read the detailed description

Eligible patients undergoing cervical conization are evaluated using transvaginal color Doppler sonography to examine alterations in bilateral uterine artery blood flow. Sonographic examinations are standardized and conducted during the follicular phase of the menstrual cycle, both preoperatively and at the one-month postoperative follow-up visit. Participant allocation to surgical modification groups is determined through a randomization process, where patients receive either hemostatic lateral sutures placed at the 3 and 9 o'clock positions of the cervix or undergo the procedure without any lateral sutures. Fresh pathology specimens are systematically weighed and measured for volume. Postoperative changes in the right and left uterine artery Resistance Index (Delta RI) are analyzed to determine the independent effects of surgical techniques, specimen physical dimensions, and histopathological lesion severity on uterine hemodynamics.

02

Conditions studied

  • Cervical Intraepithelial Neoplasia
  • Uterine Artery Hemodynamics

Keywords

  • Cervical conization
  • Uterine artery Doppler
  • Resistance index
  • Vascular resistance
  • Pregnancy complications
03

In context

Uterine Cervical Dysplasia

410 studies on the registry are indexed under Uterine Cervical Dysplasia; 77 are open to participants now.

This study's enrollment of 50 is below the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.

Browse Uterine Cervical Dysplasia studies →

Lead sponsor

Adana City Training and Research Hospital is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Regularly menstruating female patients aged between 30 and 50 years.
  2. Definitive clinical indication for cervical conization based on abnormal cervical cytology, positive HPV screening, or colposcopy-guided findings.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant pelvic pathologies that could independently alter uterine artery blood flow or Doppler indices, such as uterine fibroids, ovarian cysts, endometriosis, pelvic inflammatory disease (PID), or hydrosalpinx.
  2. Acute postoperative bleeding complications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Suture Group

    Participants assigned to undergo cervical conization with the placement of hemostatic 1/0 absorbable polyglycolic acid sutures at the 3 and 9 o'clock positions of the cervix for traction and immediate hemostasis.

    Procedure: Cervical Conization

  • Active comparator
    No Suture Group

    Participants assigned to undergo the cervical conization procedure executed without the placement of any 3 and 9 o'clock cervical lateral sutures.

    Procedure: Cervical Conization

Interventions

  • ProcedureCervical Conization

    Surgical excision of a symmetric cervical cone specimen surrounding the endocervical canal. The procedure is executed under general anesthesia using electrocautery via the Covidien Forcetriad energy platform with restricted power levels (Coagulation: 40 W, Cutting: 40 W) to minimize secondary thermal tissue damage.

06

What researchers measure

Primary outcomes

  1. Change in Uterine Artery Resistance Index (RI)

    Evaluation of bilateral uterine artery Doppler Resistance Index (RI) waveforms to measure modifications in downstream distal vascular resistance following microvascular occlusion.

    Time frame: Preoperatively and at 1 month postoperatively

07

Study locations

1 site
  • Adana City Training and Research Hospital
    Adana, 01230, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data collected during the study will not be made available to other researchers to protect participant confidentiality and comply with institutional privacy regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Oct 2018, 4 months.

Of 78 non-industry interventional studies with no phase under Uterine Cervical Dysplasia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's 4 months is below that.

Counting every sponsor, half of 82 studies reached it within 26 months; a quarter within 13 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartActual
Jun 20, 2018
Primary completionActual
Oct 30, 2018
CompletionActual
Oct 30, 2018
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07653191
Lead sponsor
Adana City Training and Research Hospital
Responsible party
Gorkem Ulger (M.D., Gynecological Oncology Surgery Specialist, Adana City Training and Research Hospital) — Principal investigator
First posted
Jun 17, 2026
Start date
Jun 20, 2018
Primary completion
Oct 30, 2018
Completion
Oct 30, 2018
Last update
Jun 17, 2026

Study contacts

Gorkem Ulger, M.D.
principal investigator · Niğde Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion